All Stories

  1. The Applicability of a Checklist for the Diagnosis and Treatment of Exocrine Pancreatic Insufficiency
  2. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)
  3. Multicentric Italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency
  4. Epidemiology, clinical features and diagnostic work-up of cystic neoplasms of the pancreas: Interim analysis of the prospective PANCY survey
  5. Genome‐wide association study identifies an early onset pancreatic cancer risk locus
  6. Evaluation and validation of the prognostic value of nutrition and immunity parameters in gastric cancer after R0 resection
  7. Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer
  8. Gossypibomas as a rare cause of common bile duct dilation
  9. Acute Pancreatitis Associated With Myotonic Dystrophy Type I
  10. The Clinical Impact of Splanchnic Ischemia on Patients Affected by Thoracoabdominal Aortic Aneurysms Treated with Fenestrated and Branched Endografts
  11. Alcohol-related chronic exocrine pancreatic insufficiency: diagnosis and therapeutic management. A proposal for treatment by the Italian Association for the Study of the Pancreas (AISP) and the Italian Society of Alcohology (SIA)
  12. A rare cause of melena in lung cancer
  13. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry
  14. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma
  15. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients
  16. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study
  17. Role of BAG3 in cancer progression: A therapeutic opportunity
  18. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma
  19. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer
  20. Endoscopic ultrasonography in chronic asymptomatic pancreatic hyperenzymemia: Why not?
  21. Levels of uric acid in erectile dysfunction of different aetiology
  22. Pancreatic enzyme replacement therapy after gastric resection: An update
  23. Diagnosis and treatment in chronic pancreatitis: an international survey and case vignette study
  24. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation
  25. Comparison of Clinical Data and Scores of Quality of Life, Anxiety, and Depression in Patients With Different Types of Intraductal Papillary Mucinous Neoplasms
  26. Response to Malleo et al.
  27. Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management
  28. Serum endocannabinoids in assessing pain in patients with chronic pancreatitis and in those with pancreatic ductal adenocarcinoma
  29. Endoscopic Ultrasonography May Select Subjects Having Asymptomatic Chronic Pancreatic Hyperenzymemia Who Require a Stricter Follow-up
  30. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival
  31. Levels of l -arginine and l -citrulline in patients with erectile dysfunction of different etiology
  32. Benign Exocrine Pancreatic Diseases in Inflammatory Bowel Diseases
  33. Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery
  34. The Health Gain Obtainable from Pancreatic Resection for Adenocarcinoma in the Elderly
  35. Can Serum Pancreatic Amylase and Lipase Levels Be Used as Diagnostic Markers to Distinguish Between Patients With Mucinous Cystic Lesions of the Pancreas, Chronic Pancreatitis, and Pancreatic Ductal Adenocarcinoma?
  36. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes
  37. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients
  38. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21
  39. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk
  40. A comprehensive analysis on expected years of life lost due to pancreatic cancer
  41. Are we ready for early discharge of patients with mild non-alcoholic acute interstitial pancreatitis?
  42. Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in Italy
  43. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review
  44. Implications and issues related to familial pancreatic cancer: a cohort study of hospitalized patients
  45. Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer
  46. Corrigendum
  47. Markers of Bone Metabolism in Patients With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma
  48. Quality assessment of the guidelines on cystic neoplasms of the pancreas
  49. Recurrence Risk Factors Analysis for Stage I Non-small Cell Lung Cancer
  50. Consensus guidelines on severe acute pancreatitis
  51. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer
  52. TERTgene harbors multiple variants associated with pancreatic cancer susceptibility
  53. Serum Markers of Myocardial Damage in Acute Pancreatitis
  54. Branch-Type Intraductal Papillary Mucinous Neoplasm of the Pancreas
  55. Quality of life in patients with long-standing chronic non-pathological pancreatic hyperenzymemia
  56. Enlarged pancreas: not always a cancer
  57. Evaluation of High Sensitive Troponin in Erectile Dysfunction
  58. Exocrine Pancreas Involvement in Celiac Disease: A Review
  59. Vitamin D and Erectile Dysfunction
  60. Different reconstruction techniques after pancreatoduodenectomy do not affect clinical and patient reported outcomes
  61. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer
  62. Antioxidant Treatment for Acute Pancreatitis
  63. Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms
  64. Clasificación Internacional y Multidisciplinaria de la Pancreatitis Aguda: Edición española 2013
  65. Immunosuppressive drugs for the treatment of autoimmune pancreatitis
  66. Antioxidants Are Not Useful in Reducing Both Pain and Inflammation in Chronic Pancreatitis
  67. Five-year overview: an update on enteral nutrition and refeeding strategy in acute pancreatitis
  68. Three-Dimensional Contrast-Enhanced Ultrasonography of Intraductal Papillary Mucinous Neoplasms of the Pancreas
  69. Long term outcome of acute pancreatitis in Italy: Results of a multicentre study
  70. BAG3 Is a Novel Serum Biomarker for Pancreatic Adenocarcinomas
  71. Contrast-Enhanced Ultrasound in the Differential Diagnosis of Exocrine Versus Neuroendocrine Pancreatic Tumors
  72. Outcomes of intraductal papillary mucinous neoplasm with “Sendai-positive” criteria for resection undergoing non-operative management
  73. Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas
  74. Einteilung des Schweregrads der akuten Pankreatitis
  75. Risk Factors for Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: A Multicentre Case–Control Study
  76. Is troponin T a useful marker of myocardial damage in acute pancreatitis? A prospective time course study
  77. ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium
  78. Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension
  79. Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium
  80. Exocrine pancreatic insufficiency in adults: A shared position statement of the Italian association for the study of the pancreas
  81. Is diabetes mellitus a risk factor for pancreatic cancer?
  82. Lack of Replication of Seven Pancreatic Cancer Susceptibility Loci Identified in Two Asian Populations
  83. Determinant-Based Classification of Acute Pancreatitis Severity
  84. Acute recurrent pancreatitis and pancreas divisum: Appearances can be deceiving
  85. Expression of the Antiapoptotic Protein BAG3 Is a Feature of Pancreatic Adenocarcinoma and Its Overexpression Is Associated With Poorer Survival
  86. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus
  87. Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis
  88. Serum Amyloid A and C-Reactive Protein Independently Predict the Recurrences of Atrial Fibrillation After Cardioversion in Patients With Preserved Left Ventricular Function
  89. Circulating Lymphocyte Subsets in Pancreatic Adenocarcinoma and Their Relationship to the Stage of the Disease
  90. Selecting families eligible for pancreatic cancer screening: Another brick in the wall for the early detection of pancreatic ductal adenocarcinoma and its precursors
  91. Treating pain in chronic pancreatitis—is the dilemma over?
  92. Autoimmune pancreatitis management: reflections on the past decade and the decade to come
  93. Preoperative Gemcitabine and Oxaliplatin in a Patient with Ovarian Metastasis from Pancreatic Cystadenocarcinoma
  94. Pancreatic ductal adenocarcinoma screening: New perspectives
  95. Usefulness of the Clavien-Dindo classification after pancreaticoduodenectomy
  96. Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders
  97. Clinical and Patient-Reported Outcomes After Pancreatoduodenectomy for Different Diseases
  98. Therapeutic management and clinical outcome of autoimmune pancreatitis
  99. The usefulness of a grading system for complications resulting from pancreatic resections: a single center experience
  100. Tyrosine Kinase Inhibitors, Pancreatic Hyperenzymemia and Acute Pancreatitis: A Review
  101. Is the pancreas affected in patients with septic shock? — a prospective study
  102. Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases
  103. Radiofrequency Ablation for Advanced Ductal Pancreatic Carcinoma
  104. Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study
  105. Cystic dystrophy of the duodenal wall is not always associated with chronic pancreatitis
  106. Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
  107. Does Ablation Technique Utilized in the Management of Unresectable Locally Advanced Pancreatic Adenocarcinoma?
  108. Practical Guidelines for Acute Pancreatitis
  109. Italian consensus guidelines for chronic pancreatitis
  110. Surgical management of acute pancreatitis in Italy: lessons from a prospective multicentre study
  111. Spontaneous Cholecystocutaneous Fistula
  112. Pancreatic Endocrine Tumors Less Than 4 cm in Diameter
  113. Total pancreatectomy: indications, operative technique, and results
  114. The Problems of Radiofrequency Ablation as an Approach for Advanced Unresectable Ductal Pancreatic Carcinoma
  115. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection
  116. Clinical Outcome of Patients Who Underwent Total Pancreatectomy
  117. Warm Water and Oil Assistance in Colonoscopy
  118. Are There Prognostic Factors Related to Recurrence in Pancreatic Endocrine Tumors?
  119. NSAIDs and Acute Pancreatitis: A Systematic Review
  120. ORIGINAL RESEARCH—ERECTILE DYSFUNCTION: Evaluation of Microalbuminuria in Patients with Erectile Dysfunction
  121. Standardized Uptake Values of 68Ga-DOTANOC PET: A Promising Prognostic Tool in Neuroendocrine Tumors
  122. Pancreatic and extrapancreatic lesions in patients with intraductal papillary mucinous neoplasms of the pancreas: a single-centre experience
  123. Serum and Urine Trypsinogen Activation Peptide in Assessing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
  124. Abdominal pain and ECG alteration: a simple diagnosis?
  125. The concept of autoimmune pancreatitis and its immunological backgrounds
  126. Water-related techniques in colonoscopy: the end justifies the means!
  127. Pharmacotherapy for acute pancreatitis
  128. Alcoholic Pancreatitis: Pathogenesis, Incidence and Treatment with Special Reference to the Associated Pain
  129. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms
  130. Painless Jaundice: Remember Alcohol and Smoking Habits for the Diagnosis
  131. Value of Both WHO and TNM Classification Systems for Patients with Pancreatic Endocrine Tumors: Results of a Single-Center Series
  132. Evaluation of Patient-Reported Outcome in Subjects Treated Medically for Acute Pancreatitis: A Follow-Up Study
  133. Patient-reported outcomes in patients with endocrine tumors of the ileum
  134. Sclerosing Cholangitis, Autoimmune Chronic Pancreatitis, and Situs Viscerum Inversus Totalis
  135. Chronic pancreatitis: Report from a multicenter Italian survey (PanCroInfAISP) on 893 patients
  136. Effect of early antibiotic prophylaxis with ertapenem and meropenem in experimental acute pancreatitis in rats
  137. Chronic asymptomatic pancreatic hyperenzymemia is a benign condition in only half of the cases: A prospective study
  138. Chronic pancreatitis: Maldigestion, intestinal ecology and intestinal inflammation
  139. Etiology of chronic pancreatitis: Has it changed in the last decade?
  140. Is asymptomatic pancreatic hyperenzymemia the same condition in adults and in children?
  141. Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas
  142. Usefulness of serum IgG4 in the diagnosis and follow up of autoimmune pancreatitis: A systematic literature review and meta-analysis
  143. Sedation on demand and lubrication during colonoscopy: should we change our minds?
  144. Diagnosis and treatment of acute pancreatitis: The position statement of the Italian Association for the study of the pancreas
  145. Hepatobiliary and pancreatic: Caroli's disease
  146. SPINK1 and PRSS1 Mutations in Benign Pancreatic Hyperenzymemia
  147. Serum Adhesion Molecules in Acute Pancreatitis
  148. Upper endoscopy and tongue piercing: please, take care of the endoscope!
  149. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs
  150. Warm Water or Oil-Assisted Colonoscopy: Toward Simpler Examinations?
  151. Serous Cystic Tumors of the Pancreas: When to Observe and When to Operate
  152. Acute recurrent pancreatitis: An autoimmune disease?
  153. Assessment of the quality of life in chronic pancreatitis using Sf-12 and EORTC Qlq-C30 questionnaires
  154. Sedation during colonoscopy and the benefits of lubrication
  155. Fecal Calprotectin Levels in Patients with Colonic Polyposis